Lanthanum
| Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
|---|---|---|---|
| Metabolic Bone Disease Medications | Lanthanum | Dose based on blood work | Administer with meals |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
|---|---|---|---|---|---|---|---|
| 139 | <0.001 | 36 | N/A | >99 | N/A | N/A | N/A |
References:
- Harrison T, Scott L. Lanthanum Carbonate. Drugs 2004; 64(9), 985-996. doi:10.1016/j.jocd.2011.07.005
- Pennick M, Dennis K, Damment S. Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate. Journal of clinical pharmacology 2006; 46(7), 738-46.